Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at the European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) Congresses

Recludix Pharma announced preclinical data for REX-8756, an oral STAT6 inhibitor, demonstrating efficacy comparable to anti-IL-4/IL-13 antibody therapies in asthma and dermatitis models with a differentiated safety profile. The compound will be presented at EAACI and RAD congresses in June 2026. REX-8756 is currently in Phase 1 clinical trials under a partnership with Sanofi.